Questions for Endeavor
This article was originally published in The Gray Sheet
Executive Summary
European regulatory authorities reviewing a CE mark application for Medtronic's Endeavor drug-eluting stent are requesting further information on the drug compound (ABT-578) supplied by Abbott. Medtronic expects Endeavor to earn European go-ahead after resolution of these "few remaining regulatory questions," the firm says in a May 31 release, acknowledging that regulators have not estimated a timeline for final review. Medtronic previously forecast a CE mark for Endeavor in mid-2005 (1"The Gray Sheet" April 15, 2005, p. 5)...